《大行报告》高盛升石药(01093.HK)目标价至25.8元 料研发可推动长期增长
高盛发表报告表示,石药(01093.HK)上月底举行了投资者日,阐述其主要研发计划及检视产品商业化的成就,该行亦见证了石药的相关里程碑,包括公司加大对创新药物的长期增长投入策略,更为多元及成熟的药品研发平台,投资者更了解其更具透明性的产品管道,相信公司未来可受惠创新产品周期的布局。
该行重申石药「买入」投资评级,上调其未来12个月目标价,由18.9元升至25.8元,此按综合方式作估值,维持对其今年每股盈利预测不变,同时升其2020年及2021年每股盈利预测各0.5%及1.5%,各至0.77及0.94元人民币,反映公司潜在推出创新药品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.